På baggrund af data for andre CYP3A4 - hæmmere forventes midazolams plasmakoncentration at blive signifikant højere, når midazolam gives peroralt.
Based on data for other CYP3A4 inhibitors, plasma concentrations of midazolam are expected to be significantly higher when midazolam is given orally.